T. Rowe Price Associates’s PharMerica Corporation PMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-15,495
| Closed | -$454K | – | 2662 |
|
|
2017
Q3 | $454K | Hold |
15,495
| – | – | ﹤0.01% | 2127 |
|
|
2017
Q2 | $407K | Sell |
15,495
-1,236
| -7% | -$30.4K | ﹤0.01% | 2137 |
|
|
2017
Q1 | $392K | Hold |
16,731
| – | – | ﹤0.01% | 2153 |
|
|
2016
Q4 | $421K | Buy |
16,731
+3,760
| +29% | +$94.9K | ﹤0.01% | 2124 |
|
|
2016
Q3 | $364K | Sell |
12,971
-6,200
| -32% | -$159K | ﹤0.01% | 2139 |
|
|
2016
Q2 | $473K | Sell |
19,171
-6,600
| -26% | -$164K | ﹤0.01% | 1983 |
|
|
2016
Q1 | $570K | Buy |
25,771
+5,080
| +25% | +$135K | ﹤0.01% | 1916 |
|
|
2015
Q4 | $724K | Buy |
20,691
+4,080
| +25% | +$128K | ﹤0.01% | 1804 |
|
|
2015
Q3 | $473K | Hold |
16,611
| – | – | ﹤0.01% | 1976 |
|
|
2015
Q2 | $553K | Hold |
16,611
| – | – | ﹤0.01% | 1956 |
|
|
2015
Q1 | $468K | Hold |
16,611
| – | – | ﹤0.01% | 2005 |
|
|
2014
Q4 | $344K | Hold |
16,611
| – | – | ﹤0.01% | 2121 |
|
|
2014
Q3 | $406K | Hold |
16,611
| – | – | ﹤0.01% | 2028 |
|
|
2014
Q2 | $475K | Hold |
16,611
| – | – | ﹤0.01% | 1978 |
|
|
2014
Q1 | $465K | Hold |
16,611
| – | – | ﹤0.01% | 1945 |
|
|
2013
Q4 | $357K | Hold |
16,611
| – | – | ﹤0.01% | 2067 |
|
|
2013
Q3 | $220K | Sell |
16,611
-31,000
| -65% | -$418K | ﹤0.01% | 2238 |
|
|
2013
Q2 | $660K | Buy |
+47,611
| New | +$675K | ﹤0.01% | 1772 |
|
T. Rowe Price Associates's PMC Position: Q4 2017 in Review
T. Rowe Price Associates sold out of PharMerica Corporation (PMC) in Q4 2017, closing a stake of 15,495 shares — an estimated $454K sold.
T. Rowe Price Associates first reported a position in PMC in Q2 2013 and held it in 18 quarters. The position peaked at $724K in Q4 2015. 0 funds tracked by Wall St. Rank hold PMC as of Q4 2017.
- T. Rowe Price Associates reported no remaining PharMerica Corporation position as of Q4 2017 after selling out during the quarter.
- T. Rowe Price Associates sold 15,495 PharMerica Corporation shares in Q4 2017, an estimated $454K.
- T. Rowe Price Associates first reported a position in PharMerica Corporation in Q2 2013 and held it in 18 quarters.
- T. Rowe Price Associates's PharMerica Corporation position peaked at $724K in Q4 2015.
- 0 funds tracked by Wall St. Rank held PharMerica Corporation as of Q4 2017.
Based on T. Rowe Price Associates's 13F filing for Q4 2017, filed 14 Feb 2018.